Back to Search Start Over

IL16 and factor V gene variations are associated with asparaginase-related thrombosis in childhood acute lymphoblastic leukemia patients

Authors :
Covida Mootoosamy
Maria Kondyli
Sophie Annaelle Serfaty
David-Étienne Tremblay
Vincent Gagné
Maïté Ribère
Caroline Laverdière
Jean-Marie Leclerc
Daniel Sinnett
Thai Hoa Tran
Maja Krajinovic
Source :
Pharmacogenomics. 24:199-206
Publication Year :
2023
Publisher :
Future Medicine Ltd, 2023.

Abstract

Aim: We previously conducted exome-wide association study in acute lymphoblastic leukemia patients and identified association of five SNPs with asparaginase-related thrombosis. Here we aimed to replicate these findings in an independent patient cohort and through analyses in vitro. Patients & methods: SNPs located in IL16, MYBBP1A, PKD2L1, RIN3 and MPEG1 genes were analyzed in patients receiving Dana-Farber Cancer Institute acute lymphoblastic leukemia treatment protocols 05-001 and 11-001. Thrombophilia-related variations were also analysed. Results: IL16 rs11556218 conferred higher risk of thrombosis and higher in vitro sensitivity to asparaginase. The association was modulated by the treatment protocol, risk group and immunophenotype. A crosstalk between factor V Leiden, non-O blood groups and higher risk of thrombosis was also seen. Conclusion: IL16 and factor V Leiden variations are implicated in asparaginase-related thrombosis.

Details

ISSN :
17448042, 14622416, and 11556218
Volume :
24
Database :
OpenAIRE
Journal :
Pharmacogenomics
Accession number :
edsair.doi...........a0944b191509f34b5b3ebef2e605747e